Form 4: Viracta Therapeutics Director Exercises Restricted Stock Units
SEC Form 4
Director Roger Pomerantz exercised restricted stock units (RSUs) for Viracta Therapeutics common stock on February 25, 2024.
Summary
- On February 25, 2024, Roger Pomerantz, a director of Viracta Therapeutics, Inc., exercised 9,034 restricted stock units (RSUs) for common stock.
- The exercise price for the RSUs was $0.00.
- Following the transaction, Pomerantz directly owns 99,375 shares of common stock and 45,172 derivative securities (RSUs).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| November 25, 2021 | First Vesting Date for the RSU Award, where one-eighth (1/8th) of the award vested. |
| February 25, 2024 | Date of transaction: Roger Pomerantz exercised 9,034 Restricted Stock Units (RSUs). |
| February 27, 2024 | Date of signature for the Form 4 filing. |
| May 25, August 25, November 25 of each year | Quarterly Vesting Dates, where one-sixteenth (1/16th) of the RSU Award vests. |
Keywords
Form 4, Viracta Therapeutics, VIRX, Roger Pomerantz, Restricted Stock Units, Director, Beneficial Ownership, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.